The identification of cancer types with frequent amplification of CDK8 and correlation of expression with survival suggests a potential role of CDK8 in the pathogenesis of CRC or its treatment response, but it does not necessarily imply that such cancers will respond to CDK8 inhibitor therapy. The gene discussed is CDK8; the disease is colorectal carcinoma.